Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$6.71	$7.08	$5.28 ▼ $14.38	$551.19M	0.86	454,424 shs	239,398 shs
DCTH Delcath Systems	$15.64 -2.0%	$13.88	$7.12 ▼ $18.23	$544.68M	0.95	387,156 shs	460,310 shs
KIDS OrthoPediatrics	$21.72 -1.7%	$21.53	$19.52 ▼ $35.99	$527.51M	1.08	199,950 shs	163,424 shs
LUCD Lucid Diagnostics	$1.31 +2.3%	$1.31	$0.68 ▼ $1.80	$141.73M	1.31	581,241 shs	731,354 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	-2.19%	+2.76%	-0.45%	-30.18%	+2.76%
DCTH Delcath Systems	-1.54%	-2.56%	+10.45%	+32.12%	+131.98%
KIDS OrthoPediatrics	-0.32%	+9.84%	-5.03%	-10.71%	-25.84%
LUCD Lucid Diagnostics	-1.54%	+4.92%	+16.36%	0.00%	+76.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVS Bioventus	2.5239 of 5 stars	3.3	0.0	0.0	0.0	4.2	1.3
DCTH Delcath Systems	3.6275 of 5 stars	3.5	5.0	0.0	3.3	2.5	0.6
KIDS OrthoPediatrics	4.3281 of 5 stars	3.4	2.0	3.9	2.4	4.2	0.6
LUCD Lucid Diagnostics	3.5258 of 5 stars	3.6	5.0	0.0	3.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.67	Moderate Buy	$14.33	113.61% Upside
DCTH Delcath Systems	3.00	Buy	$24.00	53.45% Upside
KIDS OrthoPediatrics	2.83	Moderate Buy	$35.83	64.98% Upside
LUCD Lucid Diagnostics	3.20	Buy	$3.55	170.99% Upside

Current Analyst Ratings Breakdown

Latest LUCD, DCTH, BVS, and KIDS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.50 ➝ $7.75
5/23/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $29.00
5/15/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/8/2025	KIDS OrthoPediatrics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $30.00
5/8/2025	KIDS OrthoPediatrics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/7/2025	BVS Bioventus	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$15.00
4/21/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.50
4/11/2025	KIDS OrthoPediatrics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$26.00 ➝ $24.00
4/11/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
4/9/2025	KIDS OrthoPediatrics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$567.70M	0.97	$0.53 per share	12.58	$2.80 per share	2.40
DCTH Delcath Systems	$53.85M	10.11	N/A	N/A	$0.72 per share	21.72
KIDS OrthoPediatrics	$212.45M	2.48	N/A	N/A	$16.14 per share	1.35
LUCD Lucid Diagnostics	$4.17M	33.96	N/A	N/A	($0.47) per share	-2.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	-$156.23M	-$0.48	N/A	14.59	N/A	-7.11%	15.61%	4.01%	N/A
DCTH Delcath Systems	-$47.68M	-$0.50	N/A	N/A	N/A	-150.70%	-338.16%	-104.02%	8/4/2025 (Estimated)
KIDS OrthoPediatrics	-$20.97M	-$1.75	N/A	N/A	N/A	-15.00%	-5.78%	-4.80%	8/4/2025 (Estimated)
LUCD Lucid Diagnostics	-$52.67M	-$1.34	N/A	N/A	N/A	-1,069.87%	N/A	-123.54%	8/11/2025 (Estimated)

Latest LUCD, DCTH, BVS, and KIDS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	DCTH Delcath Systems	$0.10	$0.03	-$0.07	$0.03	$16.83 million	$19.80 million
5/7/2025	Q1 2025	KIDS OrthoPediatrics	-$0.26	-$0.39	-$0.13	-$0.46	$51.68 million	$52.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
KIDS OrthoPediatrics	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	1.85	1.41	0.99
DCTH Delcath Systems	N/A	1.34	1.03
KIDS OrthoPediatrics	0.19	7.17	3.68
LUCD Lucid Diagnostics	N/A	1.18	1.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
DCTH Delcath Systems	61.12%
KIDS OrthoPediatrics	69.05%
LUCD Lucid Diagnostics	74.01%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	32.90%
DCTH Delcath Systems	17.40%
KIDS OrthoPediatrics	32.70%
LUCD Lucid Diagnostics	6.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	1,200	82.14 million	54.46 million	Not Optionable
DCTH Delcath Systems	60	34.83 million	26.24 million	Optionable
KIDS OrthoPediatrics	200	24.29 million	16.52 million	Optionable
LUCD Lucid Diagnostics	70	108.19 million	54.12 million	No Data

LUCD, DCTH, BVS, and KIDS Headlines

Recent News About These Companies

Lucid Diagnostics (NASDAQ:LUCD) Price Target Raised to $7.75 at Ascendiant Capital Markets

June 8, 2025 | americanbankingnews.com

Ascendiant Capital Markets Forecasts Strong Price Appreciation for Lucid Diagnostics (NASDAQ:LUCD) Stock

June 6, 2025 | marketbeat.com

Lucid Diagnostics Inc. (NASDAQ:LUCD) Sees Large Increase in Short Interest

June 3, 2025 | marketbeat.com

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

May 27, 2025 | prnewswire.com

Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of "Buy" from Analysts

May 24, 2025 | marketbeat.com

Lucid Diagnostics’ SWOT analysis: stock faces reimbursement hurdles amid market potential

May 21, 2025 | investing.com

Lucid Diagnostics Reports Increased Losses Amid Revenue Decline

May 16, 2025 | tipranks.com

Earnings call transcript: Lucid Diagnostics Q1 2025 highlights growth and strategic expansion

May 15, 2025 | investing.com

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

May 15, 2025 | prnewswire.com

Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript

May 14, 2025 | seekingalpha.com

Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates

May 14, 2025 | zacks.com

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

May 14, 2025 | prnewswire.com

Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know

May 7, 2025 | zacks.com

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

April 30, 2025 | prnewswire.com

Lucid Diagnostics’ EsoGuard DNA Test shows cancer detection efficacy in study

April 26, 2025 | markets.businessinsider.com

Lucid Diagnostics Reports Positive Data for EsoGuard in Study of Asymptomatic Patients

April 24, 2025 | theglobeandmail.com

Lucid reports encouraging results from EsoGuard study

April 24, 2025 | msn.com

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

April 24, 2025 | prnewswire.com

Lucid Diagnostics price target raised to $7.50 from $7 at Ascendiant

April 22, 2025 | markets.businessinsider.com

Lucid Diagnostics Closes $16.1 Million Public Offering

April 11, 2025 | tipranks.com

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

April 11, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD, DCTH, BVS, and KIDS Company Descriptions

Bioventus NYSE:BVS

$6.71 0.00 (0.00%)

As of 04:00 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Delcath Systems NASDAQ:DCTH

$15.64 -0.32 (-2.01%)

As of 04:00 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

OrthoPediatrics NASDAQ:KIDS

$21.72 -0.38 (-1.72%)

As of 04:00 PM Eastern

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Lucid Diagnostics NASDAQ:LUCD

$1.31 +0.03 (+2.34%)

As of 04:00 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time